Jeffreys Ross

Summary

Affiliation: Albany Medical College
Country: USA

Publications

  1. ncbi Antibody-based therapeutics: focus on prostate cancer
    Jeffrey S Ross
    Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
    Cancer Metastasis Rev 24:521-37. 2005
  2. ncbi Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Arch Pathol Lab Med 136:1298-307. 2012
  3. ncbi Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon
    Thanemozhi G Natarajan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road, Washington, DC 20057, USA
    Cancer Cell Int 10:13. 2010
  4. ncbi Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Clin Cancer Res 13:2831-5. 2007
  5. ncbi Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer
    Jeffrey S Ross
    Departments of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Clin Cancer Res 9:6357-62. 2003
  6. ncbi Targeted therapy in breast cancer: the HER-2/neu gene and protein
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Mol Cell Proteomics 3:379-98. 2004
  7. ncbi Breast cancer biomarkers and molecular medicine: part II
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, MC 80 Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Expert Rev Mol Diagn 4:169-88. 2004
  8. ncbi Pharmacogenomics
    Jeffrey S Ross
    Division of Molecular Medicine, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Adv Anat Pathol 11:211-20. 2004
  9. ncbi Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy
    Jeffrey S Ross
    Department of Pathology, Laboratory Medicine, Albany Medical College, Albany, New York, USA
    Drug News Perspect 22:93-106. 2009
  10. ncbi The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Adv Anat Pathol 14:353-7. 2007

Detail Information

Publications80

  1. ncbi Antibody-based therapeutics: focus on prostate cancer
    Jeffrey S Ross
    Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
    Cancer Metastasis Rev 24:521-37. 2005
    ....
  2. ncbi Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Arch Pathol Lab Med 136:1298-307. 2012
    ..KRAS testing is widely accepted in clinical practice to guide metastatic colorectal carcinoma therapeutic decisions, and there are many commercially available platforms to perform the test...
  3. ncbi Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon
    Thanemozhi G Natarajan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road, Washington, DC 20057, USA
    Cancer Cell Int 10:13. 2010
    ..We then investigated MLL2 in solid tumors of breast and colon by immunohistochemistry, and evaluated potential associations with established clinicopathologic variables...
  4. ncbi Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Clin Cancer Res 13:2831-5. 2007
    ....
  5. ncbi Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer
    Jeffrey S Ross
    Departments of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Clin Cancer Res 9:6357-62. 2003
    ....
  6. ncbi Targeted therapy in breast cancer: the HER-2/neu gene and protein
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Mol Cell Proteomics 3:379-98. 2004
    ..The review will also evaluate the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response...
  7. ncbi Breast cancer biomarkers and molecular medicine: part II
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, MC 80 Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Expert Rev Mol Diagn 4:169-88. 2004
    ..The second section will consider the prediction of therapy response using the techniques of pharmacogenetics and pharmacogenomics...
  8. ncbi Pharmacogenomics
    Jeffrey S Ross
    Division of Molecular Medicine, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Adv Anat Pathol 11:211-20. 2004
    ..This technique has generated a wealth of new information in the fields of leukemia/lymphoma, and solid tumor classification and prediction of metastasis, drug and biomarker target discovery and pharmacogenomic drug efficacy testing...
  9. ncbi Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy
    Jeffrey S Ross
    Department of Pathology, Laboratory Medicine, Albany Medical College, Albany, New York, USA
    Drug News Perspect 22:93-106. 2009
    ..Also of significant interest are the evolving lists of biomarkers proposed to predict resistance to the major anti-HER2 therapies, trastuzumab and lapatinib...
  10. ncbi The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Adv Anat Pathol 14:353-7. 2007
    ....
  11. ncbi Commercialized multigene predictors of clinical outcome for breast cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Oncologist 13:477-93. 2008
    ..A number of other assays have specific predictive goals that are most often focused on the efficacy of tamoxifen in ER-positive patients, such as the two-gene ratio test and the cytochrome P450 CYP2D6 genotyping assay...
  12. ncbi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Oncologist 14:320-68. 2009
    ....
  13. ncbi Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Adv Anat Pathol 16:204-15. 2009
    ..A number of other assays have specific predictive goals most often focused on the efficacy of tamoxifen in ER-positive patients such as the Two-gene Ratio test and the Cytochrome P450 CYP2D6 genotyping assay...
  14. ncbi Biomarker update for breast, colorectal and non-small cell lung cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Drug News Perspect 23:82-8. 2010
    ..An update is given on the biomarkers for these cancers...
  15. ncbi Update on HER2 testing for breast and upper gastrointestinal tract cancers
    Jeffrey S Ross
    Foundation Medicine Inc, Cambridge, MA, USA
    Biomark Med 5:307-18. 2011
    ....
  16. ncbi Biomarker-based selection of therapy for colorectal cancer
    Jeffrey S Ross
    Foundation Medicine Inc, Cambridge, MA, USA
    Biomark Med 5:319-32. 2011
    ..In this article, a series of novel biomarkers are considered and compared with standard-of-care markers for their potential use as pharmacogenomic and pharmacogenetic predictors of disease outcome...
  17. ncbi Breast cancer biomarkers and molecular medicine
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, MC 80 Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Expert Rev Mol Diagn 3:573-85. 2003
    ..The second section of part two will consider the prediction of therapy response using the techniques of pharmacogenetics and pharmacogenomics...
  18. ncbi Prognostic markers in prostate cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Expert Rev Mol Diagn 2:129-42. 2002
    ....
  19. ncbi Morphologic and molecular prognostic markers in prostate cancer
    Jeffrey S Ross
    Department of Pathology, Albany Medical College, Albany, New York 12208, USA
    Adv Anat Pathol 9:115-28. 2002
    ....
  20. ncbi Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Mail Code 81, 47 New Scotland Avenue, Albany, NY 12208, USA
    Mod Pathol 16:198-205. 2003
    ..Interestingly, contrary to the previously documented anti-tumor effects of TIMPs, TIMP2 expression appears to have a tumor-promoting role in PACs and warrants further investigation...
  21. ncbi Detecting recurrent bladder cancer: new methods and biomarkers
    J S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, New Scotland Avenue, Albany, New York 12208, USA
    Expert Rev Mol Diagn 1:39-52. 2001
    ..Additional biomarkers considered in the review include bladder cancer tumor antigens, growth factors, cell adhesion molecules and various molecular markers including cell cycle regulatory genes and p53 mutations...
  22. ncbi Biomarkers for the detection of bladder cancer
    J S Ross
    Department of Pathology and Labortory Medicine, Albany Medical College, Albany, New York 12208, USA
    Adv Anat Pathol 8:37-45. 2001
    ....
  23. ncbi Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Expert Rev Mol Diagn 2:531-41. 2002
    ..For the diagnostics industry this represents an unprecedented opportunity for integration, increased value and commercial opportunities for molecularly-derived tests...
  24. ncbi Antibody-based therapeutics in oncology
    Jeffreys Ross
    Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
    Expert Rev Anticancer Ther 3:107-21. 2003
    ....
  25. ncbi Atherosclerosis and cancer: common molecular pathways of disease development and progression
    J S Ross
    Albany Medical College, Department of Pathology and Laboratory Medicine, New York 12208, USA
    Ann N Y Acad Sci 947:271-92; discussion 292-3. 2001
    ....
  26. ncbi The HER-2/neu oncogene in tumors of the gastrointestinal tract
    J S Ross
    Department of Pathology and Laboratory Medicine MC 81, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Cancer Invest 19:554-68. 2001
    ....
  27. ncbi Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 104:2149-55. 2005
    ..In the current study, the authors combined trastuzumab with weekly taxanes in an attempt to improve outcomes over standard chemotherapy in patients with advanced NSCLC...
  28. ncbi The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Oncologist 8:307-25. 2003
    ..The review also evaluates the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response...
  29. ncbi Targeted therapy for cancer: the HER-2/neu and Herceptin story
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA
    Clin Leadersh Manag Rev 17:333-40. 2003
    ..The review also will evaluate the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response...
  30. ncbi Prognostic factors in prostate cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 120:S85-100. 2003
    ....
  31. ncbi MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients
    Elzbieta A Slodkowska
    Albany Medical College, Department of Pathology, Mail Code 81, 47 New Scotland Avenue, Albany, NY 12208, USA
    Expert Rev Mol Diagn 9:417-22. 2009
    ..The following article will consider the basic biology, technology, ease of clinical use, level of clinical validation and potential clinical utility of this test...
  32. ncbi Biomarker-based prediction of response to therapy for colorectal cancer: current perspective
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Am J Clin Pathol 134:478-90. 2010
    ..In this review, a series of novel biomarkers are considered and compared with standard-of-care markers for their potential use as pharmacogenomic and pharmacogenetic predictors of disease outcome...
  33. ncbi Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer
    Viktor N Goncharuk
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Ann Diagn Pathol 8:6-16. 2004
    ..Our study supports a role of these tumor suppressor and metastasis suppressor genes in the evolution and progression of NSCLC...
  34. ncbi Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer
    Seth I Rosenthal
    Department of Pathology and Laboratory Medicine, Albany Medical Center, New York, USA
    Appl Immunohistochem Mol Morphol 10:40-6. 2002
    ..HER-2/neu gene amplification when present in lobular breast cancer is a significant adverse prognostic factor...
  35. ncbi The amplified WWP1 gene is a potential molecular target in breast cancer
    Ceshi Chen
    The Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY 12208, USA
    Int J Cancer 121:80-87. 2007
    ..These results suggest that genomic aberrations of WWP1 may contribute to the pathogenesis of breast cancer...
  36. ncbi Pharmacogenomics and clinical biomarkers in drug discovery and development
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 124:S29-41. 2005
    ..This review will also consider the potential of emerging biomarkers designed to assist in the clinical development of these agents...
  37. ncbi Biomarkers in melanoma: predisposition, screening and diagnosis
    J Andrew Carlson
    Division of Dermatopathology, Albany Medical College, NY 12208, USA
    Expert Rev Mol Diagn 3:163-84. 2003
    ..In this paper, we review current and novel, potentially more accurate, biomarkers and supplementary technologies that can be used for the prevention, screening and diagnosis of melanoma...
  38. ncbi New techniques in dermatopathology that help to diagnose and prognosticate melanoma
    J Andrew Carlson
    Department of Pathology, Albany Medical College MC 81, Albany, NY 12208, USA
    Clin Dermatol 27:75-102. 2009
    ....
  39. ncbi Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma
    Ceshi Chen
    The Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY 12208, USA
    Int J Cancer 124:2829-36. 2009
    ..These findings suggest that WWP1 may play an important role in ER positive breast cancer...
  40. ncbi Targeted therapies for cancer 2004
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 122:598-609. 2004
    ....
  41. ncbi Biomarkers in melanoma: staging, prognosis and detection of early metastases
    J Andrew Carlson
    Division of Dermatopathology, Albany Medical College MC 81, Albany, NY 12208, USA
    Expert Rev Mol Diagn 3:303-30. 2003
    ..In this paper, current and novel potentially more accurate biomarkers for the staging and prognostic evaluation of melanoma patients, and for the detection of subclinical metastases are reviewed...
  42. ncbi Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Clin Cancer Res 10:2466-72. 2004
    ..To our knowledge, this is the first study demonstrating the prognostic significance of NF kappa B immunoreactivity in prostate adenocarcinomas (PACs)...
  43. ncbi The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice
    Jeffrey S Ross
    Dept of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Am J Clin Pathol 119:26-36. 2003
    ....
  44. ncbi HER-2/neu testing in breast cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 120:S53-71. 2003
    ....
  45. ncbi Anticancer antibodies
    Jeffrey S Ross
    Divisions of Molecular Medicine, Molecular Pathology, and Oncology Therapeutics, Millennium Pharmaceuticals, Cambridge, MA, USA
    Am J Clin Pathol 119:472-85. 2003
    ..Antibodies approved by the Food and Drug Administration are described in detail, as are antibodies in late and early stages of clinical development...
  46. ncbi Breast cancer biomarkers
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    Adv Clin Chem 40:99-125. 2005
    ..This chapter considers the existing ancillary tests and emerging molecular markers in breast cancer prognosis assessment and the prediction of response of breast cancer to treatment of the disease...
  47. ncbi Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas
    Gregory M Sheehan
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Hum Pathol 36:1204-9. 2005
    ..Given the significant reported variability of Smad4 in several different cancers, further studies in prostate and other tumors are warranted to elucidate its role in tumorigenesis...
  48. ncbi Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips
    James Stec
    Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    J Mol Diagn 7:357-67. 2005
    ..We conclude that multigene predictors optimized for one platform lose accuracy when applied to data from another platform due to missing genes and sequence differences in probes that result in differing measurements for the same gene...
  49. ncbi Survivin and Bcl-2 expression in prostatic adenocarcinomas
    Prabhjot Kaur
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Arch Pathol Lab Med 128:39-43. 2004
    ..Overexpression of Bcl-2 correlates with other prognostic variables and predicts disease recurrence of PACs. These data also suggest that survivin and Bcl-2 may regulate cell proliferation and cell death through different mechanisms...
  50. ncbi Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
    Haiyan Xu
    Millennium Pharmaceuticals, Cambridge, Massachusetts, USA
    J Clin Invest 112:1821-30. 2003
    ..We propose that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue...
  51. ncbi Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging
    J Andrew Carlson
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 120:S101-27. 2003
    ..We review current and potential biomarkers useful for the screening for and prevention, diagnosis, staging, and prognosis of melanoma...
  52. ncbi Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas
    Gregory M Sheehan
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Hum Pathol 38:564-9. 2007
    ..Immunohistochemical expression and prognostic significance of claudins are variable in PACs, with decreased expression of claudin-1 emerging as an independent prognostic variable warranting further study...
  53. ncbi Actin-binding protein fascin expression in skin neoplasia
    Viktor N Goncharuk
    Department of Pathology, Albany Medical College, Albany, NY 12208, USA
    J Cutan Pathol 29:430-8. 2002
    ..In cancers, some malignant cells (e.g. subsets of breast and ovarian carcinomas) express fascin. In skin cancer, the role of fascin is unknown...
  54. ncbi miRNA: the new gene silencer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 128:830-6. 2007
    ..In the future, sophisticated genomic and proteomic techniques combined with complex bioinformatics data analyses will be required to translate these recent basic science discoveries to clinically useful diagnostic tests...
  55. ncbi Expression of cysteine protease protein 32 in prostatic adenocarcinoma correlates with tumor grade
    Shahgul Anwar
    Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA
    Arch Pathol Lab Med 128:649-52. 2004
    ..Moreover, strong correlation with Gleason grade, a powerful predictor of disease progression and overall survival, suggests potential usefulness of CPP32 as a prognostic factor, especially in limited biopsy samples...
  56. ncbi DNA ploidy and cell cycle analysis in breast cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Albany Medical College, NY 12208, USA
    Am J Clin Pathol 120:S72-84. 2003
    ..This review also considers the prognostic significance and potential clinical utility of ploidy measurements, S phase calculation, and individual cell cycle regulatory biomarker expression levels...
  57. ncbi CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner
    Parul Bhargava
    Department of Pathology and Laboratory Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am J Clin Pathol 128:306-13. 2007
    ..This heterogeneity of CD79a expression in AML, megakaryocytes, and myeloid precursors is MoAb clone-dependent, likely owing to different epitope detection, and may be of diagnostic usefulness...
  58. ncbi Circulating and disseminated tumor cells in the management of breast cancer
    Jeffrey S Ross
    Department of Pathology and Laboratory Medicine, Mail Code 81, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Am J Clin Pathol 132:237-45. 2009
    ..However, before CTC/DTC testing can achieve standard-of-care status, there must be improvement in the sensitivity, precision, and reproducibility of the detection methods...
  59. ncbi Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
    J Clin Oncol 25:540-7. 2007
    ..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response...
  60. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..CONCLUSIONS: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers...
  61. ncbi Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    ..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy...
  62. ncbi Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers
    Andre M Oliveira
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Pathol 124:S16-28. 2005
    ..Other tumor suppressor genes of interest in breast cancer include the retinoblastoma gene (pRb), PTEN, p16, nm23, and maspin...
  63. ncbi Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
    Josep Domingo-Domenech
    Department of Medical Oncology and Laboratory of Experimental Oncology, Institut Clinic Malalties Hemato-Oncologiques, , University of Barcelona, Barcelona, Spain
    Clin Cancer Res 12:5578-86. 2006
    ..The interest of this view is further supported by a significant association between high IL-6 in sera of HIPC patients and decreased response to docetaxel...
  64. ncbi Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  65. ncbi Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
    Luca Gianni
    Medical Oncology, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 23:7265-77. 2005
    ..We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk...
  66. ncbi Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer
    Iris Zemzoum
    , , , , Germany
    J Clin Oncol 21:1022-8. 2003
    ..The particular prognostic effect of HER2 status on OS may reflect its ability to predict resistance to systemic therapy...
  67. ncbi Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
    Jordi Codony-Servat
    Laboratory of Experimental Oncology, Medical Oncology Department, Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
    Mol Cancer Ther 5:665-75. 2006
    ..The bortezomib-observed effects on signaling transduction molecules might be relevant to help to design mechanistic-based combination treatments...
  68. ncbi Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients
    Nadia Harbeck
    Department of Obstetrics and Gynecology and Pathology, Technical University of Munich, Munich, Germany
    J Clin Oncol 26:5036-42. 2008
    ....
  69. ncbi Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
    ....
  70. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  71. ncbi A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin
    Dimitri Talantov
    Veridex LLC, 33 Technology Dr, Warren, NJ 07059, USA
    J Mol Diagn 8:320-9. 2006
    ..Lastly, our assay demonstrated an accuracy of 76% when tested on an independent set of 48 metastatic samples, 37 of which were either a known primary or initially presented as carcinoma of unknown primary but were subsequently resolved...
  72. ncbi Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need
    Jeffrey S Ross
    Future Oncol 1:439-41. 2005
  73. ncbi Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin
    Maria A Tapia
    Laboratory of Experimental Oncology, Medical Oncology Department, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
    Cell Cycle 6:2284-92. 2007
    ..These findings suggest that selective inhibition of the canonical NF kappa B pathway is sufficient to improve doxorubicin antitumor effects...
  74. ncbi Multigene predictors in early-stage breast cancer: moving in or moving out?
    Jeffrey S Ross
    Expert Rev Mol Diagn 8:129-35. 2008
  75. ncbi Genomic microarrays in cancer molecular diagnostics: just biomarker discovery tools or future bedside clinical assays?
    Jeffrey S Ross
    Expert Rev Mol Diagn 5:837-8. 2005
  76. ncbi Targeting the ubiquitin-proteasome pathway in breast cancer
    Fatima Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:148-57. 2004
    ....
  77. ncbi Acute low back pain and radiculopathy: MR imaging findings and their prognostic role and effect on outcome
    Michael T Modic
    Division of Radiology, Spine Center, Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Radiology 237:597-604. 2005
    ..To prospectively determine in patients with acute low back pain (LBP) or radiculopathy, the magnetic resonance (MR) imaging findings, prognostic role of these findings, and effect of diagnostic information on outcome...
  78. ncbi Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases
    Leos Kren
    Department of Pathology, Faculty Hospital Brno, Czech Republic
    Appl Immunohistochem Mol Morphol 12:44-9. 2004
    ..These findings indicate an inverse relationship between survivin and bcl-2 expression and suggest that these two inhibitors of apoptosis function through different pathways in the regulation of tumorigenesis in NSCLC...
  79. ncbi Emerging cancer diagnostics. "On slide" or "off slide": that is the question
    Jeffrey S Ross
    Am J Clin Pathol 120:822-4. 2003
  80. ncbi Biomarkers in melanoma: stage III and IV disease
    Gerald P Linette
    Washington University School of Medicine, Division of Oncology, Campus Box 8056, St Louis, MO 63110, USA
    Expert Rev Mol Diagn 5:65-74. 2005
    ..In this review, the known prognostic factors in Stage III and IV melanoma are reviewed. Selected investigational therapies and associated biomarkers are also discussed...